[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637326":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":39,"centralContacts":44,"locations":52,"responsibleParty":71,"collaborators":28,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":28,"enrollmentInfo":82,"targetDuration":28,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":99,"whyStopped":28,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Centre Leon Berard","OTHER",[8,14,18],{"label":9,"type":6,"description":10,"interventionNames":11},"OSCC clinical-biological cohort","A clinical-biological cohort of 50 patients with OSCC. Blood sample and biospecimen at the time of a standard surgery.",[12,13],"Procedure: Biospecimen","Procedure: Blood sampling",{"label":15,"type":6,"description":16,"interventionNames":17},"OPMD clinical-biological cohort","A clinical-biological cohort of 50 patients with OPMD. Biospecimen at the time of a standard care.",[12],{"label":19,"type":6,"description":20,"interventionNames":21},"Cyto-OPMD clinical-biological cohort","A clinical-biological cohort of 50 patients with OPMD (Cyto-OPMD). Biospecimen via cytobrush and biopsy at the time of a standard care.",[12],[23,29,33,36],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"PROCEDURE","Biospecimen","* 1 or 2 tumoral specimen (depending on the size of the tumor).\n* 1 specimen of the healthy oral mucosa.\n* 1 OPMD specimen if applicable. The biospecimens will be collected at the time of the surgery organised for the standard routine medical care.",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Blood sampling","Blood sampling (6 mL), taken from a routine biological exam.",[9],{"type":24,"name":25,"description":34,"armGroupLabels":35,"otherNames":28},"* 1 OPMD lesion specimen.\n* 1 specimen of the healthy oral mucosa (facultative). The biospecimens will be collected during standard routine medical care.",[15],{"type":24,"name":25,"description":37,"armGroupLabels":38,"otherNames":28},"* 1 cytobrush sample.\n* 1 OPMD lesion specimen. Samples must be collected in sequence (first the cytobrush, then the biopsy collected during standard routine medical care.).",[19],[40],{"name":41,"affiliation":42,"role":43},"Philippe Zrounba, M.D.","philippe.zrounba@lyon.unicancer.fr","PRINCIPAL_INVESTIGATOR",[45,49],{"name":41,"role":46,"phone":47,"phoneExt":48,"email":42},"CONTACT","04 69 85 60 82","+33",{"name":50,"role":46,"phone":47,"phoneExt":48,"email":51},"Karène Mahtouk, Ph.D.","Karene.MAHTOUK@lyon.unicancer.fr",[53],{"facility":54,"status":28,"city":55,"state":28,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Centre Léon Bérard","Lyon","69008","France","FR",{"type":60,"coordinates":61},"Point",[62,63],4.84789,45.74906,{"lat":63,"lon":62},[66,67],{"name":41,"role":46,"phone":47,"phoneExt":28,"email":42},{"name":68,"role":46,"phone":69,"phoneExt":28,"email":70},"Pierre-Eric Roux, M.D.","+33(0)478782638","pierre-eric.roux@lyon.unicancer.fr",{"type":72,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100637326","heterogeneity-of-oral-carcinogenesis-from-preneoplasia-to-invasive-squamous-cell-carcinoma-100637326",false,"NCT07579507","Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma","HOPES","Inclusion Criteria:\n\n* I1: Male or female at least 18 years old.\n* I2: For Cohort A: patients with OSCC who undergo surgery. For cohorts B and C: patients with OPMD.\n* I3: Patient who has agreed to participate in this research and sign consent.\n* I4: Patient affiliated to a medical insurance.\n* I5: Patient who have not previously received any anticancer treatment (radiotherapy, chemotherapy, or immunotherapy)\n\nExclusion Criteria:\n\n* NI1: For cohorts B and C: Patient at high risk of bleeding, such as those receiving anticoagulant or antiplatelet therapy, those with coagulation disorders, or those with a history of severe bleeding within the two weeks prior to enrollment.\n* NI2: Pregnant or nursing woman.\n* NI3: Contraindication to general anesthesia.\n* NI4: Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...).\n* NI5: Patient under curatorial or guardianship or placed under the protection of justice.","ALL","18 Years",{"count":83,"type":84},150,"ESTIMATED","INTERVENTIONAL",[87],"NA","The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and OPMD) counterparts by scRNAseq in OSCC patients. Additionally, the study will evaluate the effectiveness of non-invasive cytobrushes as a diagnostic tool compared to traditional biopsies.",[90,91],"Oral Squamous Cell Carcinomas","Oral Potentially Malignant Disorder",[93,94,95,96,97,98],"scRNAseq","Heterogeneity of all cell population","OPMD","OSCC","cytobrush","RNAseq bulk","NOT_YET_RECRUITING","2026-05-05",{"date":102,"type":103},"2026-05-12","ACTUAL",{"date":105,"type":84},"2026-06",{"date":107,"type":84},"2035-03",{"name":5,"class":6},1]